Drug intelligence / Profile preview

Pearl-101

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules
Administration: Intravenous

Overview

Pearl-101 is a small molecule inhibitor targeting Schlafen family member 11 (SLFN11), currently under development by PearlsInMires for the treatment of gastrointestinal (GI) cancer. SLFN11 is a DNA/RNA helicase that sensitizes cells to DNA-damaging agents by inhibiting the recruitment of repair proteins to damaged DNA sites. By targeting SLFN11, Pearl-101 aims to modulate the DNA damage response in tumor cells. As of 2024, the program is in the IND-enabling stage, with the company aiming to complete IND testing by 2025 and Phase I clinical trials by 2027.

Targets

PARG (Poly(ADP-ribose) glycohydrolase)ARH3 (ADP-ribosylhydrolase 3)PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on Pearl-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl-101.

Explore the full profile